Cell proliferation of human fibroblasts and osteoblasts in osteogenesis imperfecta: Influence of age
- 1 November 1995
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 10 (11) , 1705-1712
- https://doi.org/10.1002/jbmr.5650101113
Abstract
Clinical studies indicate that as a group, osteogenesis imperfecta (OI) subjects are shorter than age‐ and sex‐matched controls. Not only somatic growth, but also cellular growth appears to be impaired, and these may be related to defects in extracellular matrix common to this disorder. We have investigated the growth characteristics of dermal fibroblasts and trabecular osteoblasts isolated from patients with OI and control subjects of various ages. Cell growth curves and cell doubling times were determined by measuring cell number using crystal violet dye binding. Growth curves were modeled by a modified logistic function, the three parameters of which are markers for biologically relevant growth parameters: the plateau value or upper asymptote, which reflects the maximum cell density upon confluence; the maximal growth rate (μm); and the lag time. Both normal human fibroblasts and osteoblasts showed an age‐dependent decrease in μm. Normal fibroblasts exhibited no age‐dependence to their upper asymptote or lag time. Fibroblasts derived from patients with OI did not have significantly different upper asymptote values, μm, or lag times when compared with normal fibroblasts. Normal osteoblasts had a decrease in upper asymptote, decrease in μm, but a relatively constant lag time with increasing age. In contrast, OI osteoblast μm was decreased relative to that of normal subjects. For osteoblasts from OI patients, decreased μm appeared unrelated to the age of the subject, whereas OI fibroblasts did exhibit an age‐dependent decrease in μm. The percentage of collagenase‐digestible protein (a measure of collagen synthesis) produced by normal human fibroblasts correlated well with μm. Treating normal human osteoblasts with the proline analogue 3,4‐dehydroproline, which destabilizes collagen triple helix formation and alters collagen synthesis, secretion, and turnover, also decreased μm. A dose response to varying concentrations of 3,4‐dehydroproline was observed for normal human bone cell μm. These data suggest a link between type I collagen synthesis and cellular proliferation.Keywords
Funding Information
- National Institutes of Health (AR 39870 (JRS), AR 42358 (NSF))
This publication has 24 references indexed in Scilit:
- Brittle bones - fragile molecules: disorders of collagen gene structure and expressionPublished by Elsevier ,2002
- Serum concentrations of procollagen I C‐terminal propeptide, osteocalcin and insulin‐like growth factor‐I in patients with non‐lethal osteogenesis irnperfectaActa Paediatrica, 1993
- Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfectaAmerican Journal of Medical Genetics, 1993
- Extracellular matrix formation by osteoblasts from patients with osteogenesis imperfectaJournal of Bone and Mineral Research, 1992
- An osteopenic nonfracture syndrome with features of mild osteogenesis imperfecta associated with the substitution of a cysteine for glycine at triple helix position 43 in the pro alpha 1(I) chain of type I collagen.Journal of Clinical Investigation, 1992
- Bone disease cracks geneticsNature, 1990
- Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro.The Journal of cell biology, 1987
- How does the extracellular matrix direct gene expression?Journal of Theoretical Biology, 1982
- Electron Microscopic and Histochemical Investigation of Osteogenesis Imperfecta TardaClinical Orthopaedics and Related Research, 1971
- Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteinsBiochemistry, 1971